Recombinant therapeutics: From bench to bedside (if your health plan concurs)

Annals of Neurology

Volumn 60, Issue 5, 2006, Pages

  Hauser, Stephen L ^a   Johnston, S Claiborne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; ETANERCEPT; INFLIXIMAB; INSULIN; INSULIN GLARGINE; MONOCLONAL ANTIBODY; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

BIOENGINEERING; DRUG COST; GENETIC RECOMBINATION; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REIMBURSEMENT; REVIEW;

EID: 33845287640     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21041     Document Type: Review

References (9)

1. Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol 2006;24:769-778.
2. Pavlou AK, Reichert JM. Recombinant protein therapeutics: success rates, market trends and values to 2010. Nat Biotechnol 2004;22:1513-1519.
3. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23:1073-1078.
4. Lawrence S. Biotech drug market steadily expands. Nat Biotechnol 2005;23:1466.
5. Johnston SC, Hauser SL. Can industry rescue the NIH? Ann Neurol 2006;60:A11-A14.
6. Hauser SL, Weiner HL. Natalizumab: immune effects and implications for therapy. Ann Neurol 2006;59:731-732.
7. Zitter M. The great debate part II: should managed care rely on cost sharing to manage big-ticket biologics? Am J Managed Care 2005;12:S153-S158.
8. Morrow T. Therapy optimization: a new model for managing high-cost biologies. Biotechnol Healthcare 2006;August:43-59.
9. Waldman M. Copycats gear up to dog biotech brands. Nature 2006;443:496-497.